Synthesis and cytotoxic evaluation of novel dimethyl [1,1′-biphenyl]-2,2′-dicarboxylates bearing 1,3,4-thiadiazole moieties

Chemistry and Biodiversity

Volumn 5, Issue 9, 2008, Pages 1743-1752

  Kong, Xiang Wen ^a   Zhang, Yi Hun ^a   Wang, Tao ^a   Lai, Yi Sheng ^a   Peng, Si Xun ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DICARBOXYLIC ACID DERIVATIVE; DIMETHYL[1,1' BIPHENYL] 2,2' DICARBOXYLIC ACID DERIVATIVE; FLUOROURACIL; METHYL 2' [[5 (BENZYLSULFANYL) 1,3,4 THIADIAZOL 2 YL]CARBAMOYL] 4,4' DIMETHOXY 5,6:5',6' BIS(METHYLENEDIOXY)(1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 2' [[5 (BENZYLSULFONYL) 1,3,4 THIADIAZOL 2 YL]CARBAMOYL] 4,4' DIMETHOXY 5,6:5',6' BIS(METHYLENEDIOXY)(1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 2' [[5 [(2 CHLOROBENZYL)SULFANYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL] 4,4' DIMETHOXY 5,6:5',6' BIS(METHYLENEDIOXY)(1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 2' [[5 [(2 CHLOROBENZYL)SULFONYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL] 4,4' DIMETHOXY 5,6:5',6' BIS(METHYLENEDIOXY)(1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 2' [[5 [(3 CHLOROBENZYL)SULFANYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL] 4,4' DIMETHOXY 5,6:5',6' BIS(METHYLENEDIOXY)(1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 2' [[5 [(3 CHLOROBENZYL)SULFONYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL] 4,4' DIMETHOXY 5,6:5',6' BIS(METHYLENEDIOXY)(1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 2' [[5 [(4 CHLOROBENZYL)SULFANYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL] 4,4' DIMETHOXY 5,6:5',6' BIS(METHYLENEDIOXY)(1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 2' [[5 [(4 CHLOROBENZYL)SULFONYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL] 4,4' DIMETHOXY 5,6:5',6' BIS(METHYLENEDIOXY)(1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 4,4' DIMETHOXY 2' [[5 [(3 METHOXYBENZYL)SULFANYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL] 5,6:5',6' BIS(METHYLENEDIOXY)(1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 4,4' DIMETHOXY 2' [[5 [(3 METHOXYBENZYL)SULFONYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL] 5,6:5',6' BIS(METHYLENEDIOXY)(1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 4,4' DIMETHOXY 2' [[5 [(3 METHYLBENZYL)SULFANYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL] 5,6:5',6' BIS(METHYLENEDIOXY)(1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 4,4' DIMETHOXY 2' [[5 [(3 METHYLBENZYL)SULFONYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL] 5,6:5',6' BIS(METHYLENEDIOXY)(1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 4,4' DIMETHOXY 2' [[5 [(4 METHOXYBENZYL)SULFANYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL] 5,6:5',6' BIS(METHYLENEDIOXY)(1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 4,4' DIMETHOXY 2' [[5 [(4 METHOXYBENZYL)SULFONYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL] 5,6:5',6' BIS(METHYLENEDIOXY)(1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 4,4' DIMETHOXY 2' [[5 [(4 METHYLBENZYL)SULFANYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL] 5,6:5',6' BIS(METHYLENEDIOXY)(1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 4,4' DIMETHOXY 2' [[5 [(4 METHYLBENZYL)SULFONYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL] 5,6:5',6' BIS(METHYLENEDIOXY)(1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 4,4' DIMETHOXY 5,6:5',6' BIS(METHYLENEDIOXY) 2' [[5 [(2 NITROBENZYL)SULFANYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL](1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 4,4' DIMETHOXY 5,6:5',6' BIS(METHYLENEDIOXY) 2' [[5 [(2 NITROBENZYL)SULFONYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL](1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 4,4' DIMETHOXY 5,6:5',6' BIS(METHYLENEDIOXY) 2' [[5 [(3 NITROBENZYL)SULFANYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL](1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 4,4' DIMETHOXY 5,6:5',6' BIS(METHYLENEDIOXY) 2' [[5 [(3 NITROBENZYL)SULFONYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL](1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 4,4' DIMETHOXY 5,6:5',6' BIS(METHYLENEDIOXY) 2' [[5 [(4 NITROBENZYL)SULFANYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL](1,1' BIPHENYL) 2 CARBOXYLATE; METHYL 4,4' DIMETHOXY 5,6:5',6' BIS(METHYLENEDIOXY) 2' [[5 [(4 NITROBENZYL)SULFONYL] 1,3,4 THIADIAZOL 2 YL]CARBAMOYL](1,1' BIPHENYL) 2 CARBOXYLATE; UNCLASSIFIED DRUG; BIPHENYL DERIVATIVE; DIPHENIC ACID; THIADIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN HEPG2; CELL STRAIN K 562; CELL STRAIN MCF 7; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; LUNG CARCINOMA; MOUTH CARCINOMA; STRUCTURE ACTIVITY RELATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; METHYLATION; SYNTHESIS; TUMOR CELL LINE;

BIPHENYL COMPOUNDS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; METHYLATION; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZOLES;

EID: 56149094121     PISSN: 16121872     EISSN: 16121880     Source Type: Journal    
DOI: 10.1002/cbdv.200890163     Document Type: Article

References (24)

1. J. X. Xie, J. Zhou, C. Z. Zhang, J. H. Yang, H. Q. Jin, X. X. Chen, Acta Pharm. Sin. 1982, 17, 23.
2. W. L. Wu, S. E. Chen, W. L. Chang, C. F. Chen, A. R. Lee, Eur. J. Med. Chem. 1992, 27, 353.
3. D.-F. Chen, S.-X. Zhang, L. Xie, J.-X. Xie, K. Chen, Y. Kashiwada, B.-N. Zhou, P. Wang, L. M. Cosentino, K.-H. Lee, Bioorg. Med. Chem. 1997, 5, 1715.
4. J. Chang, R. Chen, R. Guo, C. Dong, K. Zhao, Helv. Chim. Acta 2003, 86, 2239.
5. A. Alam, Y. Takaguchi, H. Ito, T. Yoshida, S. Tsuboi, Tetrahedron 2005, 61, 1909.
6. R. Y. Guo, J. B. Chang, R. F. Chen, X. L. Fan, J. X. Xie, Acta Pharm. Sin. 1999, 34, 439.
7. S.-X. Cheng, L.-M.Wang, J.-B. Chang, L.-B. Qu, X.-L. Chen, R.-F. Chen, Chin. J. Org. Chem. 2004, 24, 691.
8. M. S. Gujral, P. M. Patnaik, R. Kaul, H. K. Parikh, C. Conradt, C. P. Tamhankar, Cancer Chemother. Pharmacol. 2001, 47, S23.
9. M. R. Stockler, N. J. C. Wilcken, A. S. Coates, Breast Cancer Res. Treat. 2003, 81, S49.
10. A. Foroumadi, F. Soltani, H. Moallemzadeh-Haghighi, A. Shafiee, Arch. Pharm. (Weinheim) 2005, 338, 112.
11. J. A. Nelson, L. M. Rose, L. L. Bennett Jr., Cancer Res. 1976, 36, 1375.
12. A. Mastrolorenzo, A. Scozzafava, C. T. Supuran, Eur. J. Pharm. Sci. 2000, 11, 325.
13. A. Senff-Ribeiro, A. Echevarria, E. F. Silva, S. S. Veiga, M. B. M. Oliveira, Anti-Cancer Drugs 2004, 15, 269.
14. R. Asbury, J. A. Blessing, D. Moore, Am. J. Clin. Oncol. 1996, 19, 400.
15. P. F. Engstrom, L. M. Ryan, G. Falkson, D. G. Haller, Am. J. Clin. Oncol. 1991, 14, 33.
16. R. F. Asbury, J. A. Blessing, P. J. DiSaia, J. Malfetano, Am. J. Clin. Oncol. 1989, 12, 375.
17. F. Vergne, P. Bernardelli, E. Lorthiois, N. Pham, E. Proust, C. Oliveira, A.-K. Mafroud, F. Royer, R. Wrigglesworth, J. K. Schellhaas, M. Barvian, F. Moreau, M. Idrissi, A. Tertre, B. Bertin, M. Coupe, P. Berna, P. Soulard, Bioorg. Med. Chem. Lett. 2004, 14, 4607.
18. K.-Y. Jung, S.-K. Kim, Z.-G. Gao, A.-S. Gross, N. Melman, K. A. Jacobson, Y.-C. Kim, Bioorg. Med. Chem. 2004, 12, 613.
19. P. Bhattacharya, J. T. Leonard, K. Roy, Bioorg. Med. Chem. 2005, 13, 1159.
20. G. Fontanini, M. Lucchi, S. Vignati, A. Mussi, F. Ciardiello, M. De Laurentis, S. De Placido, F. Basolo, C. A. Angeletti, G. Bevilacqua, J. Natl. Cancer Inst. 1997, 89, 881.
21. T. Kawaguchi, S. Yamamoto, S. Kudoh, K. Goto, K. Wakasa, M. Sakurai, Anticancer Res. 1997, 17, 3743.
22. V. Petrow, O. Stephenson, A. J. Thomas, A. M. Wild, J. Chem. Soc. 1958, 2, 1508.
23. C. G. Wermuth, 'The Practice of Medicinal Chemistry', Academic Press, New York, London, 2003, p. 66.
24. D. R. de Magalhães Moreira, A. C. L. Leite, D. M. P. Ferreira, P. M. de Costa, L. V. C. Lotufo, M. O. de Moraes, D. J. Brondani, C. O. do Ó Pessoa, Eur. J. Med. Chem. 2007, 42, 351.